Article

OD-OS retinal device receives clearances

OD-OS has received FDA 510(k) clearance and CE mark approval for its recently released navigated retina laser therapy system (Navilas).

Grapevine, TX, and Teltow, Germany

-OD-OS has received FDA 510(k) clearance and CE mark approval for its recently released navigated retina laser therapy system (Navilas).

According to the company, the system incorporates in one device advanced imaging with retinal laser therapy in a planned and controlled way using image registration. Integrated workflow is designed to support the safety, accuracy, speed, comfort, and transparency of retina laser photocoagulation. In an effort to be ergonomic, the system also provides physicians with freedom-of-neck movement and the ability to adjust their height and proximity to the patient.

The system produces a live image of the fundus in true color, as well as fluorescein angiography with 50° field of view on a monitor, panable across the fundus. In contrast to fundus cameras or scanning laser ophthalmoscopes, this patented imaging technology is capable of real-time imaging of the retina in color-both mydriatic and non-mydriatic-while including a treatment laser to treat the retina, according to the company.

“In trials, initial accuracy results with [the device] indicate a microaneurysm hit rate of 92% as evidenced by post-treatment color overlay photographs,” reported William Freeman, MD, professor and director of the Jacobs Retina Center at the Shiley Eye Center, University of California, San Diego, during a retina subspecialty day presentation at the recent American Academy of Ophthalmology annual meeting in San Francisco, according to a press release from the company.

The device debuted in the United States in September in New York at the Retina Congress and made its first appearance in Germany in September in Frankfurt at the Vitreo-Retinal Symposium.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.